Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)